Thermo Fisher Scientific Inc. (NYSE:TMO – Get Rating) CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, August 2nd. The stock was sold at an average price of $588.36, for a total value of $5,883,600.00. Following the completion of the sale, the chief executive officer now directly owns 183,373 shares in the company, valued at $107,889,338.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Thermo Fisher Scientific Trading Up 0.3 %
Shares of TMO opened at $590.00 on Friday. The stock’s 50-day moving average is $548.67 and its two-hundred day moving average is $557.79. The stock has a market cap of $230.96 billion, a PE ratio of 31.40, a P/E/G ratio of 1.83 and a beta of 0.83. Thermo Fisher Scientific Inc. has a 12 month low of $497.83 and a 12 month high of $672.34. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.65 and a quick ratio of 1.13.
Thermo Fisher Scientific (NYSE:TMO – Get Rating) last issued its quarterly earnings data on Thursday, July 28th. The medical research company reported $5.51 EPS for the quarter, topping analysts’ consensus estimates of $4.92 by $0.59. Thermo Fisher Scientific had a return on equity of 24.36% and a net margin of 17.37%. The company had revenue of $10.97 billion for the quarter, compared to analysts’ expectations of $9.95 billion. During the same quarter in the previous year, the firm posted $5.60 earnings per share. The firm’s quarterly revenue was up 18.3% on a year-over-year basis. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 22.92 earnings per share for the current fiscal year.
Thermo Fisher Scientific Announces Dividend
Wall Street Analyst Weigh In
Several equities analysts have recently commented on TMO shares. Wells Fargo & Company lowered Thermo Fisher Scientific from an “equal weight” rating to an “underweight” rating and decreased their price target for the company from $605.00 to $525.00 in a research note on Monday, April 25th. Morgan Stanley upped their price target on Thermo Fisher Scientific from $670.00 to $678.00 and gave the stock an “overweight” rating in a report on Friday, July 29th. Barclays increased their price objective on Thermo Fisher Scientific from $630.00 to $685.00 and gave the company an “overweight” rating in a report on Monday. Finally, SVB Leerink increased their price objective on Thermo Fisher Scientific from $630.00 to $650.00 and gave the company an “outperform” rating in a report on Friday, July 29th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $661.08.
Institutional Trading of Thermo Fisher Scientific
Hedge funds and other institutional investors have recently modified their holdings of the business. Kovitz Investment Group Partners LLC increased its position in shares of Thermo Fisher Scientific by 1,359.7% during the first quarter. Kovitz Investment Group Partners LLC now owns 10,612 shares of the medical research company’s stock worth $6,268,000 after acquiring an additional 9,885 shares during the last quarter. Marietta Wealth Management LLC increased its holdings in Thermo Fisher Scientific by 4.3% in the first quarter. Marietta Wealth Management LLC now owns 12,912 shares of the medical research company’s stock valued at $7,626,000 after buying an additional 529 shares during the last quarter. California State Teachers Retirement System increased its holdings in Thermo Fisher Scientific by 0.6% in the fourth quarter. California State Teachers Retirement System now owns 708,079 shares of the medical research company’s stock valued at $472,459,000 after buying an additional 4,340 shares during the last quarter. Kayne Anderson Rudnick Investment Management LLC increased its holdings in Thermo Fisher Scientific by 1.1% in the fourth quarter. Kayne Anderson Rudnick Investment Management LLC now owns 24,890 shares of the medical research company’s stock valued at $16,608,000 after buying an additional 262 shares during the last quarter. Finally, Gryphon Financial Partners LLC increased its holdings in Thermo Fisher Scientific by 6.0% in the fourth quarter. Gryphon Financial Partners LLC now owns 1,367 shares of the medical research company’s stock valued at $912,000 after buying an additional 77 shares during the last quarter. 87.48% of the stock is owned by hedge funds and other institutional investors.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
- Get a free copy of the StockNews.com research report on Thermo Fisher Scientific (TMO)
- 3 Hotel Stocks to Consider Checking into After Earnings
- How Does Freeport McMoran Inc Compare to Its Sector Competitors?
- Can FuelCell Energy Surge Higher This Year?
- Is It Time to Take a Ride on Cedar Fair Stock?
- These Are The Top Insider Buying Stocks For July
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.